First, AR suppresses CD90 expression in primary tumors partially by upregulating HIS3H2A, which consequently results in a reduction in CD90+ tumor cell populations in the blood, thereby reducing the risk of recurrence. This evidence concerns the gene THY1 and neoplasm.